Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis

Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2023;29(3):693-704. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0330

View: 2907 Download: 157 Web of Science: 3 Crossref: 3

Review

A decade of liver organoids: Advances in disease modeling

Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, Junjun Ding, Yun-Shen Chan

Clin Mol Hepatol. 2023;29(3):643-669. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0428

View: 8408 Download: 265 Crossref: 1

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):605-622. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2022.0342

View: 4022 Download: 285 Web of Science: 6 Crossref: 11

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(3):593-604. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391

View: 3607 Download: 309 Web of Science: 5 Crossref: 7

Guideline

KASL clinical practice guidelines for management of autoimmune hepatitis 2022

Clin Mol Hepatol. 2023;29(3):542-592. Published online May 3, 2023

DOI: https://doi.org/10.3350/cmh.2023.0087

View: 3266 Download: 277 Web of Science: 1 Crossref: 3

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association

Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim

Clin Mol Hepatol. 2023;29(3):521-541. Published online July 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0202

View: 2787 Download: 180 Web of Science: 4 Crossref: 4

Snapshot

Systemic therapy in advanced hepatocellular carcinoma

Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):516-519. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0051

View: 3361 Download: 160 Web of Science: 3 Crossref: 3

Letter to the Editor

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 2170 Download: 63 Web of Science: 1 Crossref: 1

Original Article

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea

Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong

Clin Mol Hepatol. 2023;29(2):496-509. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0345 Correction in: Clin Mol Hepatol 2023;29(3):830

View: 3270 Download: 132 Web of Science: 1 Crossref: 1

Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma

Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):453-464. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0450

View: 3329 Download: 114 Web of Science: 2 Crossref: 2

Editorial

The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Young-Joo Jin

Clin Mol Hepatol. 2023;29(2):414-416. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0055

View: 4054 Download: 63

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease

Byeong Geun Song, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):411-413. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0058

View: 2040 Download: 46 Web of Science: 1 Crossref: 1

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease

Ji-Won Park, Ki Tae Suk

Clin Mol Hepatol. 2023;29(2):408-410. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0085

View: 2278 Download: 67 Web of Science: 2 Crossref: 2

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 2558 Download: 70 Web of Science: 2 Crossref: 2

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 2382 Download: 57 Web of Science: 1 Crossref: 2

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer, Mohamed Naffaa, Nimer Assy

Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0045

View: 2745 Download: 122

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 2464 Download: 81 Web of Science: 1

Implications of comorbidities in nonalcoholic fatty liver disease

Sherlot Juan Song, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0066

View: 2825 Download: 73 Web of Science: 1 Crossref: 1

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 2582 Download: 76 Web of Science: 2 Crossref: 3

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 2321 Download: 93 Web of Science: 2 Crossref: 1

The growing burden of non-alcoholic fatty liver disease on mortality

Ju-Yeon Cho, Won Sohn

Clin Mol Hepatol. 2023;29(2):374-376. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0084

View: 2202 Download: 64

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0086

View: 2584 Download: 112 Web of Science: 3 Crossref: 3

The current trends in the health burden of primary liver cancer across the globe

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(2):358-362. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0092

View: 2638 Download: 57

Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan

San-Chi Chen

Clin Mol Hepatol. 2023;29(2):352-354. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0101

View: 2437 Download: 59

Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap

Shen-Yung Wang

Clin Mol Hepatol. 2023;29(2):349-351. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0082

View: 2365 Download: 57

The prime time for management of hepatocellular carcinoma in Hong Kong

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(2):345-348. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0094

View: 2353 Download: 53

Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences

Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen

Clin Mol Hepatol. 2023;29(2):342-344. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0106

View: 2633 Download: 58 Web of Science: 1 Crossref: 2

The clinical management of hepatocellular carcinoma in China: Progress and challenges

Shan Shan, Jidong Jia

Clin Mol Hepatol. 2023;29(2):339-341. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0077

View: 2718 Download: 93 Web of Science: 1 Crossref: 1

Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma

Do Young Kim

Clin Mol Hepatol. 2023;29(2):335-338. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0107

View: 2460 Download: 51

What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?

Min Kyung Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(2):332-334. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0080

View: 2314 Download: 47

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 5586	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4795	MAFLD: How is it different from NAFLD?
Viewed By 4530	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3705	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3680	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 135	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 80	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Search